A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 16, 2015

Primary Completion Date

March 7, 2017

Study Completion Date

February 13, 2020

Conditions
Clostridium Difficile Associated Disease
Interventions
BIOLOGICAL

Clostridium difficile Vaccine

0.5 mL intramuscular injection.

BIOLOGICAL

Placebo

0.5 mL intramuscular injection

Trial Locations (17)

27612

Wake Research Associates, LLC, Raleigh

28401

PMG Research of Wilmington, LLC, Wilmington

32720

Avail Clinical Research, LLC, DeLand

33024

QPS-MRA, LLC (Broward Research Group), Hollywood

33143

QPS-MRA, LLC (Miami Research Associates), South Miami

45206

Cincinnati Childrens Hospital Medical Center, Cincinnati

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

66212

Vince & Associates Clinical Research, Inc., Overland Park

Vince & Associates Clinical Research, Inc, Overland Park

68134

Meridian Clinical Research, LLC, Omaha

77081

Texas Center For Drug Development, Inc., Houston

78229

Clinical Trials of Texas, Inc., San Antonio

78705

Benchmark Research, Austin

84109

J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

89104

Clinical Research Center of Nevada LLC, Las Vegas

96814

East-West Medical Research Institute, Honolulu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY